Improving patient access to biologics by reducing the cost of therapy and reimbursement complexity remains the most prominent unmet need in psoriasis.
By Anna Reyes, Analyst
5 August 2016
I am an Immunology & Inflammation analyst at Datamonitor Healthcare, based in the London office. I joined Datamonito...
Read full bio
Datamonitor Healthcare’s 2016 survey of 220 dermatologists in the US, Japan, and five major EU markets (France, Germany, Italy, Spain, and the UK) reveals that patient access to biologics remains the most prominent unmet need in psoriasis. Dermatologists indicate that the availability of lower cost biologics or simpler reimbursement protocols would lead to improved patient access. This suggests that, overall, psoriasis patients are undertreated, with biologic therapy restricted to those with the greatest need. According to current practices, psoriasis patients must fail traditional topical and systemic therapy before being prescribed a biologic. Indeed, key opinion leaders interviewed by Datamonitor Healthcare highlighted the disparity of biologic use between psoriasis and other autoimmune indications.
“Well I think psoriasis is a very under treated disease. If you look at psoriasis compared to say rheumatoid arthritis or Crohn’s disease or inflammatory bowel disease and you look at the patients with moderate to severe psoriasis, less than 20% are being treated systemically or with biological therapy.”
US key opinion leader
According to secondary sources, improved access to biologic therapies will lead to significant improvements in health-related quality of life and, subsequently, greater patient satisfaction with therapy. Moreover, improved disease control achieved with biologic therapies compared with traditional agents may limit long-term healthcare expenditures, including outpatient visits and inpatient hospitalizations. Interviewed key opinion leaders expect the need for affordable, efficacious, and safe therapies for the treatment of moderate to severe psoriasis to be partially addressed by the availability of biosimilars.
“I think they [biosimilars] are valuable on the market and I think the prices of a lot of these medications are terribly high. I think it is good that the price is going to come down and we are not spending too much money on these drugs all the time. So, I think it is good for that.”
EU key opinion leader
Datamonitor Healthcare’s Psoriasis: Treatment provides an in-depth analysis of psoriasis diagnosis, patient segmentation, current and future prescribing patterns, factors influencing decision-making and key treatment challenges.
Get your free demo of Datamonitor Healthcare tody. Simply fill out the form to the right >>>